The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Category Archives: Transhuman News
Industry Groups Encourage USDA Takeover of Gene Editing Regulations – AgNet West
Posted: April 20, 2022 at 10:35 am
Nearly a dozen agricultural organizations are continuing to encourage the revising of gene editing regulations. Oversight of genetically engineered food animals is currently handled by the U.S. Food and Drug Administration (FDA). Ag groups are pushing for the U.S. Department of Agriculture (USDA) to assume responsibility of animal biotechnology. In a letter addressed to Agriculture Secretary Tom Vilsack, the organizations point out the necessity in updating the regulatory approach to gene editing in livestock.
The FDAs current regulatory approach an approach that producers, other stakeholders, and Congress have repeatedly expressed concern with will only stifle U.S. producers access to much-needed innovations, the letter states. Academics, developers, and investors are unlikely to make the significant investments needed to research and develop agricultural innovations if they do not have clear, predictable criteria to achieve enforcement discretion and reasonable market access.
Signatories of the letter include the National Cattlemens Beef Association, National Milk Producers Federation, American Farm Bureau Federation, and the National Association of State Departments of Agriculture. The groups assert that changes to gene editing regulations are needed to better combat a variety of issues including diseases and challenges related to climate change. USDA has been working to advance a framework to establish a more modernized approach to regulating gene editing technologies in animal agriculture. The groups expressed support for USDA efforts in advancing the proposed rulemaking for the Regulation of Movement of Animals Modified or Developed by Genetic Engineering.
Gene editing technology offers livestock producers the opportunity to address the serious sustainability, animal health, and food security challenges facing our food supply in the 21st century, the groups note in the letter. However, this potential can only be achieved if we have federal policies that are risk-and science-based, and that permit the meaningful adoption of these products by producers, supply chains, and consumers.
Related
Read more from the original source:
Industry Groups Encourage USDA Takeover of Gene Editing Regulations - AgNet West
Posted in Genetic Engineering
Comments Off on Industry Groups Encourage USDA Takeover of Gene Editing Regulations – AgNet West
Novel Food Safety Assessments in Indonesia, Thailand, and Vietnam – Lexology
Posted: at 10:35 am
New technologies and production processes in the food industry have led to novel foods becoming increasingly important to both food manufacturers and the consuming public worldwide. This is very much the case across a number of jurisdictions in Southeast Asia.
Novel foods refer to new food production processes, foods, and ingredients that have not yet been commonly used for human consumption, so these innovative foods require safety assessments before companies can produce and market them. While rules for these safety assessments are already part of novel food regulations in several other jurisdictionssuch as the novel food regulations in the United Kingdom and European Union adopted in 2003, and the major reform of food safety laws in the United States passed in 2011 under the Food Modernization Actsimilar rules governing the assessment of novel foods are relatively new or yet to be introduced in many parts of Asia.
Nevertheless, it is important to understand the laws and practices that apply to safety assessments and the process of bringing novel foods to market in jurisdictions in the region. This article provides some clarity in this regard by summarizing important practical information on novel foods and the relevant required safety assessments in Indonesia, Thailand, and Vietnam.
Indonesia
Process and Timeline
Before submitting an application for novel food safety assessment, the applicant or a representative should first consult with BPOMs Directorate of Processed Food Standardization. This consultation can help the applicant identify the data requirements for submission.
For obtaining approval of novel foods, applicants must submit the required items through the directorates online submission system. BPOM will then check the application to verify its completeness, and will contact the applicant within five working days either to confirm that the submission is complete or to direct the applicant to rectify any shortcomings.
Once all requirements have been fulfilled, BPOM is to assess the application within 85 working daysor around 46 months in practice.
Required Documents
The application requirements differ depending on the category of novel food. There are two main categories:
Thailand
Process and Timeline
Seeking approval for novel foods consists of two stages.
In this stage, the applicant submits safety data to one of four safety assessment organizations accepted by the FDA. The maximum or estimated duration of this step depends on the organization:
Novel foods that contain any ingredient derived from a genetically modified organism (GMO) must undergo a BIOTEC review.
To apply for the FDAs approval of a novel food, the applicant must submit the letter from the safety assessment organization, along with other relevant documents, to the FDA via their online system. The FDA will consider the application and make a determination within 40 business days.
Required Documents
Vietnam
A genetically modified food contains one or several genetically engineered ingredients. New food additiveswhile not legally definedinclude new combinations of permitted food additives, food additives not included in the permitted list, and food additives included in the permitted list but used outside of the permitted categories.
A genetically modified food contains one or several genetically engineered ingredients. New food additiveswhile not legally definedinclude new combinations of permitted food additives, food additives not included in the permitted list, and food additives included in the permitted list but used outside of the permitted categories.
Self-declaration: None
Registered product declaration: USD 70
Process and Timeline
Conventional Foods. Every food product sold in Vietnam must have a declaration that it meets regulatory standards. For many types of food, a self-declaration procedure covers this requirement. However, some foods also require additional inspection and approval from the Ministry of Health via a registered product declaration.
GMOs. Food products based on GMOs that are on the Ministry of Agricultural and Rural Developments list of edible GMOs undergo the same approval procedure as other conventional food products. However, food products based on GMOs not on this list must first obtain certification of the GMOs eligibility for use as food before undergoing the approval procedure for conventional food products.
In order to apply for certification, Vietnams Council of Food Safety must have concluded that the GMO has no inordinate risks for human health, or the GMO must have been approved for use as food by at least five developed countries, with no adverse incidents having occurred.
If one of these conditions is met, the application can be submitted to the relevant department in the Ministry of Agricultural and Rural Development. Within seven working days of receiving a submission, the department will acknowledge the validity of the application or request additions.
Valid applications will then be appraised by the Genetically Modified Food Safety Councilan advisory council composed of representatives of the Ministries of Industry and Trade; Science and Technology; Agriculture and Rural Development; Natural Resources and Environment; and Health, in addition to other experts. For GMOs that have already been approved for use as food by at least five developed countries, without any recorded adverse incidents, appraisal of the application takes 60 days. For other GMOs, the maximum appraisal duration is 180 days.
Within 30 days of obtaining the appraisal results, the minister of the Ministry of Agricultural and Rural Development will either certify the GMOs eligibility for use as food, or issue a refusal clearly stating the reason.
Required Documents
Applications for certification of a food product as an edible GMO must include the following items:
If the applicant has any other unpublished reference or research materials, assessments, test reports, or scientific figures concluding that the genetically modified organisms do not negatively affect human health, those items should be included in the application.
Conclusion
New foods and ingredients are highly regulated in countries around the world, regardless of whether a jurisdiction has specific laws on novel foods. There are some common regulatory approaches and practices, but even in a single region such as Southeast Asia the rules and processes can vary. Indonesia, Thailand, and Vietnamthree especially active and well-developed regulatory regimes for food in the region, offer compliant food producers and importers a chance to access local consumers and markets. By first recognizing the requirements and regulations in these jurisdictions, and then seeking local expertise that can ensure the process is done correctly, businesses and investors can avoid costly interruptions or delays as they bring their products to market.
Here is the original post:
Novel Food Safety Assessments in Indonesia, Thailand, and Vietnam - Lexology
Posted in Genetic Engineering
Comments Off on Novel Food Safety Assessments in Indonesia, Thailand, and Vietnam – Lexology
Wrap: four organisms that could be brought back from the brink of extinction (and beyond) – Cosmos
Posted: at 10:35 am
We went on a hunt for the coolest (and spookiest) stories about bringing vulnerable animals back from the brink of extinction or, in some cases, bringing them back from the dead.
De-extincting the Tassie tiger: an Australian Jurassic Park?
In a stunning announcement in March, the University of Melbourne announced it had received $5 million in funding for a new research lab, the Thylacine Integrated Genomics Research Lab (TIGRR), which will primarily look to bring back the extinct thylacine (Tasmanian tiger) using genetic engineering and cloning techniques.
Once abundant in Tasmania, the tigers were hunted to extinction by European settlers who thought they were killing their livestock.
The ambitious new project will take a thylacine genome, salvaged from a preserved specimen, and use it as a map to re-engineer the genome inside a living cell from the creatures closest living relative, the Dunnart. Then, it will in theory clone a living thylacine from that living cell.
But, to paraphrase Jeff Goldblum, is this a case of spending so much time wondering whether they could, they never stopped to think whether they should?
Read more here.
Lost South American wildflower named extinctus rediscovered (but still endangered)
In a rare but beautiful case of redemption, the orange tropical wildflowerGasteranthus extinctus,endemic to the Andean foothills in Ecuador, was thought to have gone extinct 40 years ago.
But in a stroke of luck, a team of researchers who set out in hopes of rediscovering the plant managed to find a specimen growing, proving that its still clinging on (though still perilously endangered).
We walked into Centinela thinking it was going to break our heart, and instead we ended up falling in love, said one of the lead researchers.
Get an update of science stories delivered straight to your inbox.
Read the full article here.
Bringing back the iconic woolly mammoth
Back in 2017, scientists from Harvard University stunned the world when they announced plans to bring back the iconic woolly mammoth.
These iconic, massive elephant-like creatures had shaggy fur that helped them brave the frosty wilds of the last Ice Age.
De-extincting the mammoths, the scientists said, would be possible because mammoth DNA remains in frozen carcasses found buried in the permafrost in places like Siberia. They say theyre going to use elephant DNA to help patch up the holes, and create a living mammoth cell, which they will implant into an elephant to carry to term, giving birth to a real life woolly mammoth.
But, why do it?According to Revive and Restore, a genomic research and restoration project, the absence of the woolly mammoths from the tundra stopped the compaction of snow, meaning extreme winter cold didnt penetrate the soil, leading to the accelerated melting of the permafrost.
So, the theory goes, these new mammoths will help reverse the melting of these ice stores that are full of greenhouse gases.
Read on for more.
Bringing back the Christmas Island rat
It might be a slightly less iconic species, but the Christmas Island rat was yet another fatality of European expansion, vanishing from the island 119 years ago because of diseases brought from the strange, foreign land.
This rat still has many living relative species, making it potentially a model species for this kind of de-extinction.
Read on for more.
Read the rest here:
Wrap: four organisms that could be brought back from the brink of extinction (and beyond) - Cosmos
Posted in Genetic Engineering
Comments Off on Wrap: four organisms that could be brought back from the brink of extinction (and beyond) – Cosmos
Opinion | April 16: Russian barbarism, a statue of Boris, standardize traffic lights and other letters – Hamilton Spectator
Posted: at 10:35 am
GMO debate is not over
In his op-ed Saving the planet one bite at a time, (April 7), Prof. Sylvain Charlebois says the new United Nations Intergovernmental Panel on Climate Change (IPCC) report is worth the read but it seems he did not actually read it himself. Charlebois says, The report sees global trade and genetic engineering as part of the solution, but the report doesnt even mention genetic engineering (genetically modified organisms or GMOs). Yet he then states, it is time to put the anti-GMO rhetoric to rest. Whatever reason he has for making this passionate statement, the IPCC is not it, and readers deserve correct information. Falsely reporting on the IPCC content trivializes the serious challenge before us. Furthermore, this attempt to shut down debate over GMOs comes at a time when we need more debate, not less: as the Canadian Food Inspection Agency and Health Canada are proposing to remove environmental and food safety assessments for some genetically engineered seeds and foods.
Lucy Sharratt, co-ordinator, Canadian Biotechnology Action Network (CBAN)
Brott deserves a statue
The sudden recent death of Boris Brott in such a tragic manner is truly heartbreaking. That it should happen on a street in Hamilton, the city he loved so well, is especially painful.
Boris Brott was a world renowned maestro, and a strong proponent of this city. The enthusiasm and obvious joy he brought to his performances was always uplifting to witness.
I was lucky to see him perform here in Hamilton and more recently at the National Arts Centre in Ottawa. His enthusiasm, energy and sense of fun was always evident.
I think a fitting and appropriate tribute to Boris Brott would be to have his likeness in a statue erected in Gore Park, honouring his decades long musical contributions to Hamilton. Honouring him this way would also promote his legacy of a love for music.
Perhaps it might replace the contentious statues of John A. Macdonald or Queen Victoria. The loss of a person of Brotts stature deserves a monument at the centre of this city.
Marion Shynal, Stoney Creek
Standardize traffic lights
Who knows when a green light with a red flashing hand signal is going to yellow and one second later to red? Or countdown lights some turn red at 0; other countdowns go from 0 to a red hand signal for you to guess at how long you have to go through the intersection safely. A quick glance into your review mirror tells you that the car behind you is on your bumper; to make a quick decision to stop could end up in a collision. Split second decision. I hate it! You slow down nearing an intersection not knowing weather you can safely make it through the light only having to speed up as the light hasnt yet changed and the guy behind you is honking his horn pushing you through. Then you worry if this was a red-light camera intersection. I ask myself every day, why cant Hamilton synchronize all the traffic lights for continuity, so that every driver knows when to slow down to stop?
Saving mine for buck-a-beer
The letter writers complaining about getting a refund on the licence stickers are getting tiring. Really? I never got a red cent back from their beloved Liberals, in fact I was gouged enough on everything from electricity to public services to make up for a centurys worth of overpayment to their provincial coffers.
I, for one, appreciate that I dont have to spend money on stickers for my vehicles and was grateful to get my refund. You want to donate your refund to Del Duca or any other cause, knock yourself out. Im saving mine for buck-a-beer.
In praise of journalists
If not for journalists, we would not have found out that the abundance of rapid tests in Ontario were given to private schools. In fact they were given more tests than LTC homes and paramedics put together. I am a proud supporter of my local newspaper and thankful for the truth seekers out there. Keep up the good work the general public needs to know the truth
Robin Magder Pierce, Hamilton
Depraved Russian soldiers
For the children, written in Russian, on the side of an exploded missile, in the midst of dozens of Ukrainian dead. Unarmed civilian, women, children and aged. Can we imagine much that is more barbaric, uncivilized and depraved? We wonder if this dedication was the sick humour of the commanding officer, or was a suggestion from petulant Putin personally. It certainly leaves no doubt as to their evil intentions. I shall never visit Russia.
Edward A. Collis, Burlington
Superrich of the world, unite!
Regarding Liberal-NDP deal will mean major tax hikes (April 1): The manifesto of the 21st century: Superrich of the world, unite!
Nicholas Christoforou, Ancaster
See more here:
Opinion | April 16: Russian barbarism, a statue of Boris, standardize traffic lights and other letters - Hamilton Spectator
Posted in Genetic Engineering
Comments Off on Opinion | April 16: Russian barbarism, a statue of Boris, standardize traffic lights and other letters – Hamilton Spectator
Unfair Politicization, Corruption, and the Death of Modern Olympism – The Globe Post
Posted: at 10:35 am
Chinese leader Xi Jinping helda grand ceremonyon April 8 to celebrate the success of the Beijing Olympics. Perhaps it is just because of the success Xi was bragging about thatmodern Olympism, once admired by generations of people from around the world, is dead.
The cause of death of modern Olympism is twofold: corruption and hyper-and-unfair-politicization which includes the ascendance of nationalism.
Few people are so naive as to believe that the Olympics are, or could ever be, devoid of politics. Indeed, since its inception, the modern Olympic Games have become part of geopolitical history, often reflecting political tensions between nation-states.
At the 1920 Summer Olympics in Antwerp, Belgium the first Games held after World War I nations that lost in the war, such as Germany, were banned from participating. This punitive measure would have violated the principle of political neutrality enshrined in the current version of the Olympic Charter, although early versions of the Charter did not contain such a stipulation.
Sixteen years later, perhaps in part as an act of revenge or vindication, a re-emerging Germany transformed the event into a nationalistic and ideological contest as the host of the 1936 Summer Olympics in Berlin.
During the Cold War, international sports competitions were used as a vehicle for regimes to declare the superiority of their respective political systems. In recent years, the politicization of the Olympic Games has escalated to an unprecedented level, mainly at the hands of Russia and China.
Chinas communist regime exploited the 2008 Beijing Olympics to the fullest extent possible. The Games were a political project designed to demonstrate, both domestically and abroad, the rise of China under the leadership of the Chinese Communist Party (CCP).
The 2014 Sochi Winter Olympics were staged in large part to display the strength of Russian President Vladimir Putin, who used the Games as an opportunity to bolster the image of Russias strength in the lead-up to the authoritarian states annexation of Crimean in February and March of that year.
Thepoliticizationof the Olympic movement was always inevitable, but it is itsunfair politicizationthat has killed modern Olympism.
Such unfair politicization was on full display at the 2022 Beijing Winter Olympics. The Chinese government extensively politicized the 2022 Beijing Olympics while simultaneously slandering dissenting voices of Chinese human rights victims, activists and groups, and the democratic governments of other countries. It claims that such individuals and groups are politicized and contradict the Olympic spirit.
According to the Olympic Charter, the goal of the Games is to place sport at the service of the harmonious development of humankind, with a view to promoting a peaceful society concerned with the preservation of human dignity.
Genocide such as is happening to Uyghurs in Xinjiang is the antithesis of the harmonious development of humankind, and forced labor tramples on human dignity, rather than preserving it.
Ouracts of politicization, meant to defend universal fundamental ethical principles as set forth in the Charter such as peacefully publicizing and protesting the past and present atrocities committed by the CCP were prohibited in Beijing and across China.
The athletes, warned in advance by Chinese officials to remain silent on political matters while in China, literally feared for their freedom and safety if they spoke out.
The modern Olympics have long become a hyper-nationalized event. The Olympic Charter stipulates that the Games are competitions between athletes in individual or team events and not between countries. However, in reality, no Olympic athlete stands alone. Every Olympian is required to be a national of the country of the National Olympic Committee which is entering such competitor.
Olympic athletes are part of teams representing nations. The modern Olympic Games have turned into a competition between nations. Victory, measured by medal count, glorifies and validates the nation and its ruling regime, and is used to purportedly demonstrate the greatness of the nations leader.
Just like Adolf Hitler, Xi wanted the 2022 Beijing Winter Olympic Games to validate and demonstrate Chinese superiority and his own greatness as Chinas leader. He also wanted the Chinese flag, raised and waved around during the Games, to mobilize nationalist sentiment.
The Olympics have become a dangerous instrument of nationalism, which in China means Han chauvinism. As such, anyone in China who might have wanted to politicize the 2022 Games by speaking out about and defending universal ethic principles, such as protesting the genocide of Uyghurs in Xinjiang, would have been deemed an enemy of Xi, the CCP regime, and even the entire nation.
This is the anthesis of fair play, which is a core tenet of the Olympic spirit.
Moreover, the fact that the modern-day Olympics have become a multibillion-dollar business operation virtually ensures that corruption is the rule rather than the exception. This includes doping and, eventually, genetic engineering of competitors especially by depraved, morally-bankrupt totalitarian states like China and Russia.
Compared to democratic nations, authoritarian states like China and Russia also devote vastly more resources to training athletes and bribing the IOC to host the Olympics. These countries give out huge bonuses to medalists who bring glory to their country. And, of course, there are lucrative business opportunities that follow.
The Olympic Games have become one-third politics, one-third money, and one-third competition.
The spirit of modern Olympism has suffered a gradual death of a thousand cuts, due primarily to the intense and ever-increasing politicization of the Games and fueled by the rampant corruption of participating and hosting countries (some more than others) and the IOC itself.
If the integrity of modern Olympism can ever be redeemed, certain changes must take place:
First, competition must be between individual athletes. Naturally, every athlete has his or her own roots, nationality, and citizenship, but none of these factors should be a prominent part of the Games. There should be no national teams, nor should any national flags be raised during the Games.
Second, any politicization of the Games must be carried out in a fair, free, and peaceful manner.
Third, the host country must ensure freedom of expression and freedom of press for all Olympic participants and the media. Any complaints about breaches of these freedoms must be investigated, and, if substantiated, the host country must face severe consequences.
Unless major improvements are made to ensure that the Olympics are about athletic greatness and not political prowess or nationalistic fervor, the trend of declining interest in the Olympic Games will inevitably continue.
Read the original:
Unfair Politicization, Corruption, and the Death of Modern Olympism - The Globe Post
Posted in Genetic Engineering
Comments Off on Unfair Politicization, Corruption, and the Death of Modern Olympism – The Globe Post
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of Buy from Analysts – Defense World
Posted: at 10:35 am
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR Get Rating) have earned a consensus rating of Buy from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.00.
A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Jasper Therapeutics in a report on Monday, February 28th. They set an overweight rating and a $10.00 price target on the stock. Credit Suisse Group cut their price target on Jasper Therapeutics from $15.00 to $10.00 and set an outperform rating on the stock in a report on Friday, February 25th. Finally, Zacks Investment Research raised Jasper Therapeutics from a sell rating to a hold rating in a report on Thursday, January 20th.
JSPR stock traded down $0.13 during midday trading on Tuesday, reaching $2.72. The company had a trading volume of 62,997 shares, compared to its average volume of 85,363. The stocks 50 day moving average price is $3.58. Jasper Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $18.88.
Jasper Therapeutics Company Profile (Get Rating)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
See Also
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Posted in Genetic Engineering
Comments Off on Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of Buy from Analysts – Defense World
India Biolabs Need Stringent Regulations – ED Times
Posted: at 10:35 am
New Delhi (India), April 20: India is preparing to become a global player in the life sciences, fueled by its recent economic boom and a drive to diversify its portfolio with biotechnology. In this article, we look at Indias biological research history, current situation, and expected future growth. Indias greatest difficulty in realizing its ambitions will be to educate, recruit, and support the next generation of scientists. Such issues concern the United States and Europe, but they are especially acute in developing countries that are rushing to achieve scientific brilliance at a rate that may be faster than their current educational and faculty support institutions would allow.
Biotechnology is an important component of Indias national health agenda and a potential source of economic growth. Recognizing the critical role that biology will play in the twenty-first century, the Indian government is expanding and establishing several new biological research institutes, which will result in the creation of several new roles for life science experts. Funds are increasingly becoming accessible for cutting-edge equipment, reducing the formerly significant discrepancy in support facilities between Indias best research institutes and those in the United States and Europe. India is becoming a more attractive site for biological research and a rich base for emerging biotechnology businesses. However, until India attracts and encourages its 6 brightest young people to pursue research, success will not be proportional to the amount of money invested.
Many academic institutions and businesses in the United States and Europe are looking to collaborate with India, the worlds largest democratic country. Having Indian scientists on their faculty or postdoctoral fellows/graduate students in their laboratories has long been beneficial to Western institutions (perhaps benefitting more than India itself). Western scientists, on the other hand, have a limited understanding of Indias scientific and educational systems.
There are about 800 medical and healthcare R&D institutions in India, as well as 575 medical colleges, 350 universities, over 15,000 pharmaceutical and biopharmaceutical enterprises, and an uncountable number of healthcare entities and diagnostics laboratories that handle biomedical material. To govern biotechnology research, there are biosafety committees, a review committee on genetic manipulation, and a genetic engineering advisory group.
Companies are actively working on pharmaceuticals that must be used for an extended period of time, a departure from the conventional idea of minimal medication and quick recovery.
At 2003, USA Today reported on hundreds of diseases caused by humans coming into touch with germs in US biolabs in the US and other parts of the world, including the Middle East, Southeast Asia, CIS countries, and Africa. To evade the gaze of the law, its reasonable to imagine that US biolabs have completely moved such risky operations out of the US and into these other regions.
Given the lack of rules and oversight in India, American biolabs appear to have free reign to undertake trials and experiments. Even from Indian official inspection authorities, most such operations are well guarded and kept secret. Because American biolabs are concerned about public backlash and class action lawsuits in the United States, they have decided to conduct their trials in less regulated third-world nations such as India.
For example, India welcomes foreign investment and is ready to turn a blind eye when biotech companies undertake dangerous trials on an uninformed, ignorant, and illiterate population. Its worth noting that the people chosen for trials are frequently from the poorest parts of society, with little knowledge of the law, the testing procedure, or access to legal counsel.
According to the Indian defence establishment, the Surat plague in 1994, which killed 55 people and forced half of the citys population to flee, was an example of biolab leakage. Various news sources from the time mention the American CDC. There were allegations that CDC labs in Almaty, Kazakhstan, had created a germ with an additional protein ring.
For example, at a cost of $107,000, the US Defense Threat Reduction Agency financed three-year research effort on the highly pathogenic Avian Influenza virus was carried out in Haryana, Kerala, and Odisha. The projects purpose was to gather HPAI positive samples in order to assess the diseases spread and strength.
This isnt a one-off occurrence. At 2019, investigations showed that the US Centers for Disease Control and Prevention (CDC) had secretly financed Nipah Virus research in a BSL2 laboratory in Karnataka. Because the virus is so deadly, these testing can only be performed in a BSL4 level lab.
Between 1967 and 1973, the US Army collaborated with the Bombay Natural History Society in India to perform a Migratory Animal Pathological Survey. The Indian Parliament eventually objected, citing concerns that the study could be used for bio-warfare, forcing the initiative to be halted.
The Northeastern states of Assam, Manipur, Meghalaya, and Tripura were also targeted by American laboratories. The US Ministry of Defenses Defense Threat Reduction Agency conducted an Ebola research project in these areas, collecting human and bat blood. The National Center for Biological Sciences in Bangalore conducted the experiments.
It is all too clear that India, like other third-world and developing countries, is a puppet in the hands of US biopharmaceutical companies that are abusing regulatory procedures and abusing their financial power to do whatever they want, regardless of the repercussions. This must be changed. India should adopt tighter restrictions and control for such facilities conducting trials or research in the country in order to protect India from suffering from potential biological dangers.
Read the original here:
India Biolabs Need Stringent Regulations - ED Times
Posted in Genetic Engineering
Comments Off on India Biolabs Need Stringent Regulations – ED Times
What you need to know about natural, organic and vegan wines – Atlantic City Weekly
Posted: at 10:34 am
If you are seeking a naturally lower calorie wine, look for dry wines with a lower ABV, such as Prosecco (brut or extra dry), dry Riesling, or Gamay. These wines typically fall on a spectrum of 80 to 120 calories per glass.
Q: Karen S. from Margate asks, Whats the difference between a natural wine and an organic wine?
A: Hi Karen! Natural wines and organic wines have a lot in common. Most significantly they share a concern for the earth and sustainable practices, but there are also several key differences.
To be certified organic by the USDA, a wine must be made without genetic engineering, and it must undergo a rigorous process of inspections and assessments. The grapes must be grown organically without synthetic fertilizers, and all other ingredients such as yeast and fining agents must be certified organic, as well. While sulfites are commonly added to wines as an additional preserving agent or to enhance flavor, organic wines cannot have added sulfites. Wines labeled as made with organic grapes have slightly less restrictions, but it is still a feat for winemakers to achieve this certification.
Natural wine, on the other hand, is not a legal certification. Rather, its a loose term that refers to wines made with little to no intervention by the winemaker. This means grapes are grown without the assistance of pesticides, grapes are handpicked, and juice is fermented into wine using only native yeasts. These yeasts occur naturally on the fruit, and winemakers allow fermentation to start spontaneously, rather than controlling fermentation with the addition of cultured yeasts. While natural wines wont necessary be certified organic, one could argue that they exemplify the most ancient, non-invasive method of winemaking.
Excerpt from:
What you need to know about natural, organic and vegan wines - Atlantic City Weekly
Posted in Genetic Engineering
Comments Off on What you need to know about natural, organic and vegan wines – Atlantic City Weekly
Exercise and psoriasis: Links and more – Medical News Today
Posted: at 10:26 am
Physical activity can help improve psoriasis flares and increase periods of remission. Activity may further reduce the risk of developing other illnesses, such as heart disease and diabetes.
Physical activity offers many health benefits, especially for people with psoriasis. It can help them maintain a moderate weight and reduce the risk of developing certain diseases, such as heart disease and type 2 diabetes.
However, the sweat, heat, and stress of working out may also trigger or aggravate psoriasis symptoms. Pain and fatigue are also common issues that make it challenging for people with psoriasis to exercise.
This article discusses how exercise can help with psoriasis and provides tips for effective and safe activities for people with psoriasis.
Psoriasis affects approximately 3.2% of the United States population and about 23% of the worlds population.
Further research suggests that psoriasis occurs in 3.6% of white people, 1.9% of African American people, and 1.6% of Hispanic people.
This condition occurs equally among males and females.
It is an autoimmune skin condition that causes crusty, flaky patches called plaques to occur on the skins surface. These plaques may appear red on light skin and purple or violet on darker skin.
Psoriasis plaques can appear anywhere but commonly occur as small patches on:
Learn more about the signs and symptoms of psoriasis here.
A person may alternate between periods of active disease, called a flare, and periods of inactivity or remission. Symptoms can range from mild to severe, depending on the type of psoriasis a person has.
A person with psoriasis is also at an increased risk of arthritis, depression, diabetes, and heart disease.
Specific triggers can cause symptoms to appear or worsen. These vary from person to person but include:
Learn more about psoriasis in our dedicated hub.
The National Psoriasis Foundation recommends that people with psoriasis do at least 30 minutes of moderate exercise plus strength training at least five times a week.
A 2018 study found that intense physical activity might help decrease the prevalence of psoriasis. It also indicated that exercise may also benefit a persons mental health linked to the diagnosis of psoriasis and the impact on quality of life.
Another 2018 study found that diet and exercise effectively combat oxidative stressors and improve disease severity in people with psoriasis.
Obesity is a common cardiovascular risk factor in psoriatic disease. People with psoriasis may have low physical activity levels, which puts them at risk of having a stroke.
Research suggests exercise can help reduce weight and improve the severity of psoriasis in people with overweight.
A 2020 study showed that people with psoriasis tend to avoid exercise because they are concerned about:
A person should speak with their doctor or dermatologist to explore exercise options suitable for their skin needs.
Below are some tips to ensure a safe and effective workout.
As a general rule, avoid activities that cause flares or pain. Low impact, low intensity workouts, such as a stroll or a leisurely bike ride, might be more suitable.
Excessive sweating can trigger symptoms. People should avoid hot yoga and other exercises that cause excessive sweating. Inverse psoriasis is a form of psoriasis that occurs in areas where the skin folds, and sweat is a trigger that aggravates symptoms.
Some people experience stress as a result of having psoriasis, and, in turn, stress often aggravates this condition.
Doing too much exercise or performing cardio or higher intensity workouts may trigger the bodys stress response.
Higher-intensity workouts do not suit everyone, as excessive exercise can aggravate symptoms. However, people who manage their symptoms well may be able to tolerate more rigorous exercises, such as running and high intensity interval training (HIIT).
People with psoriatic arthritis, a potential complication of psoriasis, should avoid high impact exercises that put too much stress on weakened joints. Instead, they can opt for low impact activities, such as swimming and cycling.
Learn about the exercises for psoriatic arthritis here.
Tight clothing can worsen skin sensitivity, irritate the skin, and aggravate psoriasis patches during workouts.
Loose, breathable clothing and moisture-wicking fabrics help pull moisture away and allow it to evaporate fast.
Learn more about the best clothing for workouts here.
Warming up before exercise is crucial to prepare the muscles and reduce stiffness to avoid injuries. In the same way, finish activities with a proper cool-down, like some light stretching or a slow-paced walk.
Read more about the benefits of stretching.
Aim for consistency and frequency rather than duration. Physical activity may include taking the stairs instead of the elevator and walking to run errands.
If a person feels stiff or tense, they may switch their workouts and focus on a range of motion and flexibility exercises.
Learn more about stretching and flexibility here.
Working out may cause a person to sweat and lose skin moisture. A person should replenish lost fluids with proper hydration, which can help the skin stay moisturized and prevent flares in people with psoriasis.
Learn about the benefits of staying hydrated here.
If a person does not feel confident in a gym or a flare hinders their performance, they can exercise at home. There are plenty of workout videos online, including strength training, yoga, and core workouts.
Learn about the best home workouts here.
A person considering exercising for the first time could discuss options with a doctor or healthcare professional. They may be able to offer advice about what to avoid or recommend an assessment with a physical therapist.
Learn more about physical therapy here.
Aside from exercise, other alternative treatments can help manage psoriasis.
Learn more about home remedies for psoriasis here.
Psoriasis is a lifelong condition. While it has no cure, treatments and lifestyle changes, such as exercise and diet, can reduce symptoms and improve quality of life.
Psoriasis puts people at risk of other diseases that can affect their health and quality of life, including stroke, obesity, and cardiovascular diseases.
Many factors can hinder a person with psoriasis from exercising. However, not doing so can cause them to miss out on the health benefits that working out can offer.
Exercising improves a persons physical and mental health and can also reduce flares and the risk of developing other health conditions associated with psoriasis.
At the same time, a person should be mindful about how they exercise, know what to avoid, and what to do when an exercise leads to a flare.
See the original post:
Exercise and psoriasis: Links and more - Medical News Today
Posted in Psoriasis
Comments Off on Exercise and psoriasis: Links and more – Medical News Today
Episode 6: Emerging and Novel Therapeutics in the Management of PsA – Medscape
Posted: at 10:26 am
This transcript has been edited for clarity.
Elaine Husni, MD, MPH: Welcome to this Medscape InDiscussion episode six. We're going to talk about emerging and novel therapeutics in the treatment of psoriatic arthritis. I'm particularly excited today because we have Dr Ana-Maria Orbai, who's both a friend and colleague. She is an assistant professor of medicine in the division of rheumatology at the Johns Hopkins University School of Medicine. And she also directs the psoriatic arthritis program at her institution. It is definitely a treat to have her here and to talk about some really interesting new therapeutics in psoriatic arthritis. Before I begin, I'd love to ask Ana-Maria, do you recall one of any of your first experiences with a psoriatic arthritis patient and what made you interested to become an expert in this field?
Ana-Maria Orbai, MD, MHS: First of all, thank you, Dr Husni, for the generous introduction. It's my pleasure to be here. Yes, of course I recall starting with psoriatic arthritis. We didn't have much in the beginning. We were still following in the footsteps in terms of both the framework for evaluating our patients as well as the therapy choices. Since then, the clinical data have expanded. We have a lot of new therapeutics. We have head-to-head trials, so there are many more treatment choices than before, and there is the possibility of adapting the treatment to the patient's own presentation and psoriatic disease phenotype. It's a very exciting time for psoriatic disease.
Husni: I agree. I remember when you and I were going to these meetings national meetings there'd be these huge exhibits for rheumatoid arthritis (RA) and these little exhibits for psoriatic arthritis. And now we're on equal footing. It's fun to see how it's exploded. I wanted to start off with a case if that is okay with you. He's a 46-year-old construction worker. He had longstanding psoriasis, using topicals for a long time. He had an episode of dactylitis in his second toe, and he was placed on methotrexate. Unfortunately, he didn't really like the way that it made him feel so he's really been on and off of methotrexate throughout the year or two. But luckily, his dactylitis did subside after a while. A few months later, he did have some worsening skin, mostly pretty classic plaque psoriasis, on his extensor surfaces his elbows and knees. He was started on a tumor necrosis factor (TNF) inhibitor and noticed that his skin really cleared up and that it was doing pretty well. That takes us to about 6 months before his visit with me. Why he went to see me is that he found it really difficult because he has to wear these special shoes at work these construction shoes and he's noticed a lot of pain by his heel to the point where it was really difficult for him to bend down. He was really having a hard time at work. His current rheumatologist did some x-rays and some bloodwork and said that everything was pretty normal. So he was getting a little frustrated and he wanted to see if there's anything better than adalimumab, which he was on for his psoriatic arthritis, or if there was something else going on. But he just really was quite debilitated at work. So I wanted to talk to you to see how you might approach this particular patient in terms of whether or not he should stay on and be more compliant with the methotrexate along with the adalimumab. Would you consider switching and maybe talking about some of the emerging treatments that may be better in a patient like this?
Orbai: Very interesting case for sure. A common scenario in our clinics is where patients may do well initially, or the disease may be controlled for them to continue on their current therapy. But then new symptoms emerge. In your case, it sounds like it's the lower extremities. We're hearing about pain, wearing boots, standing at work. So I am thinking, without examining the patient, just imagining and thinking: It either could be arthritis, MTPs, tarsus, ankles, subtalar joint, or with heel pain, plantar fascia pain, right? Could this be enthesitis or could these be combined? It's very common for our treatments to lose efficacy over time. It sounds like he's been on this treatment for 1 year. It's not uncommon for it to lose efficacy, especially since methotrexate was on and off. This could be one case where antidrug antibodies could have been developed, and that's why the biologic no longer works. Or maybe the psoriatic arthritis just figured another way to become active, going around adalimumab. I would definitely look into switching the medication fronts for this patient, also considering the patient's preference. It sounds like he's not very enthusiastic about continuing methotrexate in the first place, so maybe we should work with that as well and think, What else do we have in our toolkit? The first mechanism of action that comes to mind and for which we have head-to-head trials with adalimumab, would be interleukin (IL)-17 inhibition. While we have used this and we're familiar with this mechanism of action first for several years now, we have an emerging IL-17 pathway inhibitor, which is a dual inhibitor of IL-17A and -F, bimekizumab. We've all seen it, the phase 2b trial results with bimekizumab, and we're awaiting the phase 3 results. This pathway would definitely be of consideration.
Husni: I agree with you. A common scenario is where somebody does really well on a biologic and the expectations are here, right? When they start to have that waxing and waning course or any new symptoms and you elegantly pointed out that enthesitis could be playing a huge role because we are not seeing lots of changes on x-ray over time or bloodwork. Yet, he's having interference for some of his work and daily activities, which really makes us wonder about some of these other manifestations of psoriatic arthritis, such as enthesitis, as you brought up. This is where some of these new treatments for me become really interesting because now we're no longer just looking at general efficacy for psoriatic arthritis. We are really raising the bar and looking at different manifestations clinical presentations of the disease. I would love to hear a little bit more on some of these early studies on bimekizumab. What is your conclusion to some of these early trials?
Orbai: We could start with the psoriasis trials where we've seen much higher efficacy with inhibiting the dual pathway, and I am very hopeful that we can expect the same augmented effect in in the psoriatic musculoskeletal disease as well. I am very much looking forward to the phase 3 trial results. From the phase 2b trial, we saw that on the ACR 50 outcome, about 50% of the patients achieved this higher bar of efficacy. We also noted that although the primary outcome was selected at 12 weeks in this phase 2b trial, there was evidence that the magnitude of responses increased over time through weeks 16 and 20 of therapy. I think that's very exciting. For enthesitis, many of the results in the phase 2b trial were exploratory simply due to sample size and looking at multiple doses. For enthesitis, improvement in the MASES enthesitis score, were numerically higher than placebo, which is very encouraging. It does make sense that an IL-17 inhibitor would work better for enthesitis because we know that enthesitis is mediated through the IL-23 and IL-17 axes. I definitely look forward to seeing outcomes specifically on enthesitis with this new mechanism of action.
Husni: I agree. The ability to have outcome measures now, whether its MASES scores, has really elevated the way that we look at trials coming because I'm not just looking at joint and skin count now, I'm curious about dactylitis, enthesitis, axial involvement, and the ability for certain subsets of these therapeutics to work on some manifestations and not others. I do find enthesitis to be a little bit harder overall because the physical exam sometimes is difficult. Then, in addition, trying to understand the different outcome measures that they're using for enthesitis and whether or not this would be good in our patients. But nonetheless, so happy to see data coming out in head-to-head trials. I'm really looking forward to phase 3 and getting some more information on this drug. I really think that it'll make some difference in our field and I'm excited that new options are still coming out. The next issue I wanted to talk about are oral agents that you and I are familiar with from RA but yet are getting approved in psoriatic arthritis, and those are the JAK inhibitors. As you know, we probably have some more initial comfort in the RA world as they were approved their first. But now, we're seeing some safety challenges. I'd love to hear how you think about the JAK inhibitors in psoriatic arthritis.
Orbai: Indeed, safety is very important; in the psoriatic program, we have it lined up right with efficacy. I always talk to my patients about the balance being on just enough medicine to get us to the treatment goals while staying safe. That could be one medicine or a combination, depending on how active the psoriatic disease is. But safety is an important discussion with the recent data on JAK inhibitors. We know that in Europe, there's the recommendation to not prescribe these drugs to people older than age 65 because of the concern for risk for infection, heart disease, and thrombosis. Data from the safety studies taught us about increased risk. Interestingly, with the JAK inhibitor mechanism compared with the TNF inhibitor mechanism, which I think is very relevant for practice, there is an increased risk for heart disease as well as cancer. Clinicians were prepared to notice this increased risk on the basis of our knowledge of the mechanism of action. I don't think it's that surprising to us. To see those data, though, is very important and helps us put the mechanism of action in the context of our clinic. We have patients of different ages with different risk, and I think it's very, very important to tailor therapies to each of our patients. For example, I would agree that maybe in patients with certain comorbidities, you'd have to think twice about prescribing a JAK inhibitor, right? Somebody with a history of deep vein thrombosis (DVT) or with known cardiovascular disease that frequently happens in psoriatic arthritis probably should not be on a JAK inhibitor unless we had no other choice. If we had to do that, then I would definitely tighten the monitoring and the management of the additional risk factors. Somebody who may be a cancer survivor, obviously we wouldn't challenge with that mechanism of action, and we have other options which I would prioritize first.
Husni: Those are really interesting points. The initial enthusiasm was that this was oral, and there was some mindset that oral is always safer than injections. At least that's how some of my patients have been looking at this. The excitement at the beginning was the method of taking this and allowing more freedom for these patients. But then the labeling change really gave us pause to say, "Okay, maybe there are subsets that should avoid JAK inhibitors." We also saw such great efficacy, as I'm sure you did in RA. I don't think I was ready to let it go completely. But in my practice now, I probably reserve it for the younger age group, and in the older than 50-55 age group, I tend not to use the JAK inhibitors as freely as I probably did before some of these safety concerns. This past American College of Rheumatology (ACR) meeting had some really interesting new data that were really trying to quantify this risk rather than just saying risk/no risk. So, I think there's more to come. I don't think I'm ready to give up, but I have taken a pause, like you said, in these certain, more vulnerable groups. But I do think having an oral option that does work for the joints is really exciting because that's sometimes where I find some of the newer mechanisms fall in the joint space, and I am looking for something.
Orbai: We don't know everything about these drugs. For example, I'll tell you about a case of a 30-year-old man with psoriatic arthritis. He had comorbid irritable bowel disease (IBD) and he was bed-bound because of arthritis of the hips, and in between infections and his flares, there was no question about hip replacement. I completely ran out of medications in his case, and then we decided: Well, you are on DVT prophylaxis because you're pretty much bedbound let's try a JAK inhibitor. And that was what basically got him out of bed. And now he's exercising. Things are not perfect, but we have MRIs that have shown that his synovitis in his hips improved. So there's definitely a nuance in how people respond to these therapies and what's driving the disease at target tissue level. As long as we learn how to use these drugs and subset our patients, then we can manage the risks. The problem is when we have to go blindly with recommending first-line, second-line, third-line the one-size-fits-all approach won't work. And that's what our problem is because we try to have a pattern that will suit everyone, and that's just not real life.
Husni: It's not just the science, but it's the art of medicine, right? Even though the science tells us this is all approved for psoriatic arthritis and efficacious, we know that it's still the art of delivering these meds in the right patients at the right time.
Last but not least, I do have to talk about the IL-23 inhibitors because they obviously have been around in the psoriasis space, and they've been very comfortable with them. We now have the first IL-23 approved, guselkumab, for psoriatic arthritis. I just recently heard of risankizumab being approved for psoriatic arthritis. It is exciting that data are coming out with the joints. I'd love to hear your take on whether you've been using a lot of IL-23 inhibitors and when to use them in patients with psoriatic arthritis.
Orbai: I have been and it's so exciting to now have two because insurance coverages are so different. Having two choices allows us to cover more patients if these drugs are needed. IL-23s are very convenient in terms of dosing. It's very attractive to have a loading dose 4 weeks apart and then maintenance treatment with an injection that patients get every 8 or every 12 weeks. So great dosing flexibility. I'm trying to start them early on. Maybe I just diagnosed a patient with psoriatic arthritis. Maybe we just started methotrexate and we're weighing whether we go up on the methotrexate or whether we start something else. When patients are in the moderate, low disease activity level after my first intervention, adding an IL-23 inhibitor to their baseline methotrexate, for example, makes me less worried for risk for infection. This could be an easy add-on that I'm trying to implement earlier on in clinic, and I've had good results with this strategy and patients like the convenience of this injection. Not to mention that some patients come back and tell me, "Doctor, the next day or 2 days after this injection, my skin stopped itching." It's nice to have an initial effect which gives the patients optimism that the rest of the goals will be achieved. So it's very exciting to have these.
Husni: I couldn't agree more that in addition to getting excited about new classes, we have some unmet needs to learn how to really get better at giving this to the right patient at the right time. I always look forward to seeing you at our meetings, and I'm sorry that we haven't been able to see each other in person, but it's really nice to have you on this podcast. I would love to ask you the same question that I ask everybody who joins me. Are you up for that? If you were cooking in your kitchen, what are the first three ingredients for a successful treatment for patients with psoriatic arthritis?
Orbai: My first is aligning with the patient's goals. Our patients walk into our office. They need help with concerns. They are concerned that this is never going to go away. That they are never going to be able to get their real life back. Or maybe they are concerned to go on a drug that may have all these serious side effects trying to assess what's bothering them the most. What's their most important goal and fear it's very important. And then once we're aligned, the rest of the ingredients: having the specialty center, which allows me to consult with other specialists like dermatologists, colleagues in cardiology, colleagues in the Inflammatory Bowel Disease Center, which are common conditions and comorbidities that our patients come with. Having that framework of a specialized center is very helpful because I can lean on my colleagues with cases that are more complicated. The third ingredient is making sure that we have the discussion with the patient that this is a long journey that we're embarking on: It's going to involve monitoring and assessing whether we are at treatment target, and it's a team approach. We will always adjust the plan and are working together in getting them where they want to be.
Husni: Well, thanks to Ana-Maria, those are really great pearls of wisdom. It was really a joy to have you. Thank you for taking time out to talk with us.
Orbai: Thank you. My pleasure.
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update
Treatment Guidelines in Psoriatic Arthritis
Bimekizumab in Patients with Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
See more here:
Episode 6: Emerging and Novel Therapeutics in the Management of PsA - Medscape
Posted in Psoriasis
Comments Off on Episode 6: Emerging and Novel Therapeutics in the Management of PsA – Medscape